拟肽类3-胰凝乳蛋白酶样蛋白酶抑制剂的研究进展  

Research progress on peptide 3-chymotrypsin-like protease inhibitors

作　　者：石玉 张国宁[1] 朱梅[1] 王玉成[1] SHI Yu;ZHANG Guoning;ZHU Mei;WANG Yucheng(Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences,Beijing 100050,China)

机构地区：[1]中国医学科学院医药生物技术研究所,北京100050

出　　处：《现代药物与临床》2025年第1期215-223,共9页Drugs & Clinic

基　　金：国家自然科学基金青年科学基金项目(82204207)。

摘　　要：冠状病毒是一类广泛存在、可感染人畜并引起严重急慢性呼吸道系统疾病的病原体。3-胰凝乳蛋白酶样蛋白酶(3CL蛋白酶)是一种位于冠状病毒非结构蛋白nsp5上的半胱氨酸蛋白酶,被认为是广谱抗冠状病毒极具吸引力的靶标之一。拟肽类3CL蛋白酶抑制剂具有更高的靶向性、更广泛的抑制谱、更低的不良反应。总结了已上市的奈玛特韦、来瑞特韦、先诺特韦、阿泰特韦和处于临床试验阶段的拟肽类3CL蛋白酶抑制剂的研究进展。Coronavirus is a type of pathogen that is widely present,can infect humans and animals,and cause serious acute and chronic respiratory system diseases.3-Chymotrypsin like protease(3CL protease)is a cysteine protease located on the non-structural protein nsp5 of the coronavirus,and is considered one of the highly attractive targets for broad-spectrum anti coronavirus therapy.Peptide 3CL protease inhibitors have higher targeting,wider inhibition spectrum,and lower adverse reactions.This article summarizes the research progress of the marketed drugs such as nirmatrelvir,leritrelvir,simnotrelvir,atilotrelvir,and the peptide 3CL protease inhibitors currently in clinical trials.

关 键 词：拟肽类3-胰凝乳蛋白酶样蛋白酶抑制剂 冠状病毒 3-胰凝乳蛋白酶样蛋白酶 奈玛特韦 来瑞特韦 先诺特韦 阿泰特韦 

分 类 号：R974[医药卫生—药品]